Xeris Biopharma Holdings, Inc.
XERS
$6.96
-$0.22-3.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 75.22% | 46.28% | 30.01% | 11.92% | -2.13% |
| Total Depreciation and Amortization | -0.96% | -3.23% | -4.84% | -4.07% | -4.87% |
| Total Amortization of Deferred Charges | 22.92% | 32.81% | 47.00% | 36.37% | 27.47% |
| Total Other Non-Cash Items | 195.62% | 78.48% | 155.30% | 79.24% | 184.06% |
| Change in Net Operating Assets | -214.14% | -514.79% | -743.60% | -40.13% | 134.18% |
| Cash from Operations | 133.53% | 57.19% | 35.15% | 21.36% | 55.41% |
| Capital Expenditure | 25.26% | 42.29% | 67.25% | 61.64% | 65.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.65% | 30.44% | 23.02% | 253.73% | 211.38% |
| Cash from Investing | -0.84% | 35.66% | 33.81% | 181.33% | 183.18% |
| Total Debt Issued | -100.00% | -100.00% | -100.00% | -- | 2.21% |
| Total Debt Repaid | -- | 200.00% | -- | -- | -- |
| Issuance of Common Stock | 1,743.88% | 518.22% | 489.90% | 198.28% | 30.03% |
| Repurchase of Common Stock | -162.70% | -152.55% | -131.79% | -270.07% | -268.71% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -898.40% | 100.00% | -898.40% | -21,593.33% |
| Cash from Financing | -65.10% | -105.44% | -106.28% | 2,342.28% | -29.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 152.34% | -85.94% | -137.57% | 107.45% | 138.12% |